Floatz Rating
B62/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03136146CT.gov Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | — | Recruiting | — | — | — |
NCT02199184CT.gov Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT01363128CT.gov Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Burkitt Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Humax-Cd20 (this asset) | M.D. Anderson Cancer Center | P2 | B · 62 |
| Nivestim | Fred Hutchinson Cancer Center | P4 | BBB |
| Vincristine Sulfate | AIDS Malignancy Consortium | P2 | BBB |
| Vindesine | PETHEMA Foundation | P4 | BBB |
| Cyclophosphamide | AIDS Malignancy Consortium | P4 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Cytarabine | AIDS Malignancy Consortium | P4 | BBB |
| Etoposide | AIDS Malignancy Consortium | P4 | BBB |
| Romidepsin | M.D. Anderson Cancer Center | P2 | BBB |
+42 more in the Burkitt Lymphoma cohort
Other indications for Humax-Cd20
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Chronic Lymphocytic Leukemia | — | P4 | BBB · 78 |
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 74 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Humax-Cd20 in Burkitt Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/humax-cd20-burkitt-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →